EGFR and non-small cell lung carcinoma: Somatic gain-of-function mutations affecting the tyrosine kinase (TK) domain of EGFR are common in NSCLC, particularly adenocarcinoma, and predict responsiveness to EGFR-targeting tyrosine kinase inhibitors (TKIs) (20).